Literature DB >> 26476406

An insoluble frontotemporal lobar degeneration-associated TDP-43 C-terminal fragment causes neurodegeneration and hippocampus pathology in transgenic mice.

Adam K Walker1, Kalyan Tripathy1, Clark R Restrepo1, Guanghui Ge1, Yan Xu1, Linda K Kwong1, John Q Trojanowski2, Virginia M-Y Lee3.   

Abstract

Frontotemporal dementia (FTD) causes progressive personality, behavior and/or language disturbances and represents the second most common form of dementia under the age of 65. Over half of all FTD cases are classified pathologically as frontotemporal lobar degeneration (FTLD) with TAR DNA-binding protein of 43 kDa (TDP-43) pathology (FTLD-TDP). In FTLD-TDP brains, TDP-43 is phosphorylated, C-terminally cleaved, lost from the nucleus and accumulates in the cytoplasm and processes of neurons and glia. However, the contribution of TDP-43 C-terminal fragments (CTFs) to pathogenesis remains poorly understood. Here, we developed transgenic (Tg) mice with forebrain Camk2a-controlled doxycycline-suppressible expression of a TDP-43 CTF (amino acids 208-414, designated 208 TDP-43 CTF), previously identified in FTLD-TDP brains. In these 208 TDP-43 Tg mice, detergent-insoluble 208 TDP-43 CTF was present in a diffuse punctate pattern in neuronal cytoplasm and dendrites without forming large cytoplasmic inclusions. Remarkably, the hippocampus showed progressive neuron loss and astrogliosis in the dentate gyrus (DG). This was accompanied by phosphorylated TDP-43 in the CA1 subfield, and ubiquitin and mitochondria accumulations in the stratum lacunosum moleculare (SLM) layer, without loss of endogenous nuclear TDP-43. Importantly, 208 TDP-43 CTF and phosphorylated TDP-43 were rapidly cleared when CTF expression was suppressed in aged Tg mice, which ameliorated neuron loss in the DG despite persistence of ubiquitin accumulation in the SLM. Our results demonstrate that Camk2a-directed 208 TDP-43 CTF overexpression is sufficient to cause hippocampal pathology and neurodegeneration in vivo, suggesting an active role for TDP-43 CTFs in the pathogenesis of FTLD-TDP and related TDP-43 proteinopathies.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26476406      PMCID: PMC5007600          DOI: 10.1093/hmg/ddv424

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  52 in total

1.  Phosphorylated high molecular weight neurofilament protein in lower motor neurons in amyotrophic lateral sclerosis and other neurodegenerative diseases involving ventral horn cells.

Authors:  G Sobue; Y Hashizume; T Yasuda; E Mukai; T Kumagai; T Mitsuma; J Q Trojanowski
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion.

Authors:  Johannes Brettschneider; Vivianna M Van Deerlin; John L Robinson; Linda Kwong; Edward B Lee; Yousuf O Ali; Nathaniel Safren; Mervyn J Monteiro; Jon B Toledo; Lauren Elman; Leo McCluskey; David J Irwin; Murray Grossman; Laura Molina-Porcel; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2012-03-18       Impact factor: 17.088

3.  TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.

Authors:  Hans Wils; Gernot Kleinberger; Jonathan Janssens; Sandra Pereson; Geert Joris; Ivy Cuijt; Veerle Smits; Chantal Ceuterick-de Groote; Christine Van Broeckhoven; Samir Kumar-Singh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-03       Impact factor: 11.205

4.  Molecular analysis and biochemical classification of TDP-43 proteinopathy.

Authors:  Hiroshi Tsuji; Tetsuaki Arai; Fuyuki Kametani; Takashi Nonaka; Makiko Yamashita; Masami Suzukake; Masato Hosokawa; Mari Yoshida; Hiroyuki Hatsuta; Masaki Takao; Yuko Saito; Shigeo Murayama; Haruhiko Akiyama; Masato Hasegawa; David M A Mann; Akira Tamaoka
Journal:  Brain       Date:  2012-10-03       Impact factor: 13.501

5.  Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies.

Authors:  Kunihiro Uryu; Hanae Nakashima-Yasuda; Mark S Forman; Linda K Kwong; Christopher M Clark; Murray Grossman; Bruce L Miller; Hans A Kretzschmar; Virginia M-Y Lee; John Q Trojanowski; Manuela Neumann
Journal:  J Neuropathol Exp Neurol       Date:  2008-06       Impact factor: 3.685

6.  Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Masato Hasegawa; Tetsuaki Arai; Takashi Nonaka; Fuyuki Kametani; Mari Yoshida; Yoshio Hashizume; Thomas G Beach; Emanuele Buratti; Francisco Baralle; Mitsuya Morita; Imaharu Nakano; Tatsuro Oda; Kuniaki Tsuchiya; Haruhiko Akiyama
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

7.  A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank.

Authors:  Jon B Toledo; Vivianna M Van Deerlin; Edward B Lee; EunRan Suh; Young Baek; John L Robinson; Sharon X Xie; Jennifer McBride; Elisabeth M Wood; Theresa Schuck; David J Irwin; Rachel G Gross; Howard Hurtig; Leo McCluskey; Lauren Elman; Jason Karlawish; Gerard Schellenberg; Alice Chen-Plotkin; David Wolk; Murray Grossman; Steven E Arnold; Leslie M Shaw; Virginia M-Y Lee; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2013-08-24       Impact factor: 21.566

8.  Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.

Authors:  Lionel M Igaz; Linda K Kwong; Edward B Lee; Alice Chen-Plotkin; Eric Swanson; Travis Unger; Joe Malunda; Yan Xu; Matthew J Winton; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

9.  Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease.

Authors:  Joanna L Jankowsky; Hilda H Slunt; Victoria Gonzales; Alena V Savonenko; Jason C Wen; Nancy A Jenkins; Neal G Copeland; Linda H Younkin; Henry A Lester; Steven G Younkin; David R Borchelt
Journal:  PLoS Med       Date:  2005-11-15       Impact factor: 11.069

Review 10.  Clinical review. Frontotemporal dementia.

Authors:  Jason D Warren; Jonathan D Rohrer; Martin N Rossor
Journal:  BMJ       Date:  2013-08-06
View more
  23 in total

1.  Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43).

Authors:  Friederike Hans; Marita Eckert; Felix von Zweydorf; Christian Johannes Gloeckner; Philipp J Kahle
Journal:  J Biol Chem       Date:  2018-08-17       Impact factor: 5.157

2.  Effect of TDP43-CTFs35 on Brain Endothelial Cell Functions in Cerebral Ischemic Injury.

Authors:  Xiaotian Xu; Changwen Zhang; Jianxiong Jiang; Mei Xin; Jiukuan Hao
Journal:  Mol Neurobiol       Date:  2022-05-18       Impact factor: 5.590

3.  Distinct brain-derived TDP-43 strains from FTLD-TDP subtypes induce diverse morphological TDP-43 aggregates and spreading patterns in vitro and in vivo.

Authors:  Sílvia Porta; Yan Xu; Tagan Lehr; Bin Zhang; Emily Meymand; Modupe Olufemi; Anna Stieber; Edward B Lee; John Q Trojanowski; Virginia M-Y Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2021-05-21       Impact factor: 8.090

Review 4.  Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.

Authors:  Alistair Wood; Yuval Gurfinkel; Nicole Polain; Wesley Lamont; Sarah Lyn Rea
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 5.  Molecular, functional, and pathological aspects of TDP-43 fragmentation.

Authors:  Deepak Chhangani; Alfonso Martín-Peña; Diego E Rincon-Limas
Journal:  iScience       Date:  2021-04-21

Review 6.  Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways.

Authors:  Mohamed A Eldeeb; Mohamed A Ragheb; Marwa H Soliman; Richard P Fahlman
Journal:  Neurotox Res       Date:  2022-01-18       Impact factor: 3.911

7.  Elevated Hapln2 Expression Contributes to Protein Aggregation and Neurodegeneration in an Animal Model of Parkinson's Disease.

Authors:  Qinqin Wang; Qinbo Zhou; Shuzhen Zhang; Wei Shao; Yanqing Yin; Yandong Li; Jincan Hou; Xinhua Zhang; Yongshun Guo; Xiaomin Wang; Xiaosong Gu; Jiawei Zhou
Journal:  Front Aging Neurosci       Date:  2016-08-23       Impact factor: 5.750

Review 8.  Cysteine Modifications in the Pathogenesis of ALS.

Authors:  Cristiana Valle; Maria Teresa Carrì
Journal:  Front Mol Neurosci       Date:  2017-01-23       Impact factor: 5.639

9.  Microglia-mediated recovery from ALS-relevant motor neuron degeneration in a mouse model of TDP-43 proteinopathy.

Authors:  Krista J Spiller; Clark R Restrepo; Tahiyana Khan; Myrna A Dominique; Terry C Fang; Rebecca G Canter; Christopher J Roberts; Kelly R Miller; Richard M Ransohoff; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Neurosci       Date:  2018-02-20       Impact factor: 24.884

10.  Onset of disorder and protein aggregation due to oxidation-induced intermolecular disulfide bonds: case study of RRM2 domain from TDP-43.

Authors:  Sevastyan O Rabdano; Sergei A Izmailov; Dmitrii A Luzik; Adam Groves; Ivan S Podkorytov; Nikolai R Skrynnikov
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.